Herpes simplex glycoprotein vaccine (Genentech- GlaxoSmithKline)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameHerpes simplex glycoprotein vaccine (Genentech- GlaxoSmithKline)
Drug Alias Name单纯疱疹病毒糖蛋白疫苗Genital herpes prophylaxis vaccineSimplirixHSV-gD-t2GSK-208141
ClassificationVaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsHerpes Simplex
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[23] 
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsHerpes Simplex

Other Information

ATC CodeN/A
Related LinksN/A